So it has a different mechanism. So that’s typically used ... as you continue to increase the levodopa, carbidopa doses to treat the OFF episodes that worsen over time, you end up bumping ...

So it has a different mechanism. So that’s typically used earlier in the ... As we all know, as patients progress through the disease, as you continue to increase the levodopa, carbidopa doses to ...

Cerevel Therapeutics’ Parkinson’s disease therapy tavapadon has shown efficacy in a phase 3 trial, reinforcing its blockbuster potential and no doubt delighting AbbVie, which has agreed to buy ...

While patients with Parkinson’s initially start taking oral drugs like levodopa and carbidopa to manage symptoms, these often fail to control symptoms throughout a 24-hour period and tend to ...

Celon Pharma’s PDE10A inhibitor has reduced involuntary movements in a phase 2 trial of individuals with Parkinson’s disease.

Supernus Pharmaceuticals reported its Q4 2024 earnings, revealing a revenue of $174.2 million, surpassing the projected $150.24 million. Despite this, the company's earnings per share (EPS) fell ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, and safety of rasagiline are reviewed. Summary: Rasagiline is a novel, investigational propargylamine that irreversibly and ...

However, recent studies demonstrating that (aggregating) α-synuclein can be internalized by cells suggests a mechanism based on cell–cell transmission. [19–22] The neurons initially affected ...